Pimecrolimus, yet another intriguing local immunomodulator, has been approved for use in atopic dermatitis in individuals of more then 2 years of age. However, its indications are now being extended to include a variety of inflammatory dermatoses, which are identified in the current article with a proviso that their use should be considered only as an alternative when conventional modalities have failed.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1080/09546630701280642 | DOI Listing |
Publication Analysis
Top Keywords
pimecrolimus intriguing
8
intriguing topical
4
topical immunomodulator
4
immunomodulator pimecrolimus
4
intriguing local
4
local immunomodulator
4
immunomodulator approved
4
approved atopic
4
atopic dermatitis
4
dermatitis individuals
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!